Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Probiotics01:22

Probiotics

41
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
41
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

896
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
896
Functions of the Gut Microbiota01:18

Functions of the Gut Microbiota

2
The gut microbiota includes trillions of microorganisms that colonize the human gastrointestinal tract, including bacteria, archaea, viruses, and fungi. This complex ecosystem plays a critical role in maintaining intestinal and systemic health. Most of these microbes inhabit the large intestine, establishing a relatively stable and diverse community that contributes to gut homeostasis through various metabolic, immunological, and protective mechanisms.Dominant bacterial phyla, such as...
2
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

854
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
854

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of remote radar based vital sign acquisition for emergency department patient triage.

Frontiers in medical technology·2026
Same author

Distinct pain profiles across irritable bowel syndrome subtypes: results from the Rome Foundation Global Epidemiology Study.

Internal and emergency medicine·2026
Same author

Comparative Study on Burden, Features and Determinants of Disorders of Gut-Brain Interaction Between Southern Europe and the Rest of Continent: Results From the Rome Foundation Global Epidemiology Study.

United European gastroenterology journal·2026
Same author

Burden, features and factor associated with disorders of gut-brain axis in Italy: results from the Rome foundation global epidemiology study.

Internal and emergency medicine·2026
Same author

Switching anti-VEGF agents does not improve visual outcomes in branch retinal vein occlusion-related macular edema.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Privatization of ophthalmology: unveiling disparities in the surgical arena.

Israel journal of health policy research·2026
Same journal

Needle-based confocal laser endomicroscopy and artificial intelligence in pancreatic cystic lesions: Insights and clinical advances.

Best practice & research. Clinical gastroenterology·2026
Same journal

Evidence-based approach to the diagnosis, management and surveillance of pancreatic cystic lesions: from the guidelines to the clinical practice.

Best practice & research. Clinical gastroenterology·2026
Same journal

Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound.

Best practice & research. Clinical gastroenterology·2026
Same journal

Predictive risk models for the diagnosis and cancer progression of pancreatic cysts.

Best practice & research. Clinical gastroenterology·2026
Same journal

Preface.

Best practice & research. Clinical gastroenterology·2026
Same journal

Endoscopic ultrasound-guided treatment of pancreatic lesions.

Best practice & research. Clinical gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Mar 23, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K

Probiotics in functional bowel disorders.

Keren Hod1, Yehuda Ringel2

  • 1Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Best Practice & Research. Clinical Gastroenterology
|April 7, 2016
PubMed
Summary
This summary is machine-generated.

Probiotics show promise for treating functional bowel disorders (FBDs), common gastrointestinal issues impacting quality of life. This review examines evidence for using probiotics to target gut microbiota in FBD management.

Keywords:
Functional bowel disordersIntestinal mocrobiotaIrritable bowel syndromeProbiotics

More Related Videos

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

10.6K
Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.1K

Related Experiment Videos

Last Updated: Mar 23, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

10.6K
Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.1K

Area of Science:

  • Gastroenterology
  • Microbiology
  • Neurogastroenterology

Background:

  • Functional bowel disorders (FBDs) are prevalent gastrointestinal conditions impacting patient quality of life and incurring significant healthcare costs.
  • Current FBD theories focus on brain-gut axis dysfunction affecting motility and sensation.
  • Emerging evidence implicates the intestinal microbiota in FBD pathogenesis and symptom development.

Purpose of the Study:

  • To explore the potential role of probiotic interventions in managing FBDs.
  • To review existing pre-clinical and clinical evidence supporting probiotic use for FBDs.
  • To provide current recommendations for clinical practice regarding probiotics in FBD treatment.

Main Methods:

  • Review of pre-clinical studies on probiotics and FBDs.
  • Analysis of clinical trial data on probiotic efficacy in FBD patients.
  • Synthesis of current literature to inform clinical recommendations.

Main Results:

  • Pre-clinical data suggest microbiota alterations contribute to FBDs.
  • Clinical studies show potential benefits of specific probiotics for FBD symptom management.
  • Evidence supports targeting the intestinal microbiota for FBD treatment.

Conclusions:

  • Probiotic interventions represent a promising therapeutic strategy for FBDs.
  • Further research is needed to optimize probiotic selection and application for FBDs.
  • Healthcare providers should consider probiotics as an adjunct therapy for FBDs based on current evidence.